Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Company Deals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Fineline Cube Mar 14, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...

Company Medical Device

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st

Fineline Cube Mar 14, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...

Company Drug

China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM

Fineline Cube Mar 14, 2025

China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...

Company Drug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

Fineline Cube Mar 14, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...

Company Drug

Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials

Fineline Cube Mar 14, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...

Company Medical Device

Johnson & Johnson MedTech Gains FDA Clearance for MONARCH QUEST with AI Algorithms

Fineline Cube Mar 14, 2025

US major Johnson & Johnson MedTech announced receiving U.S. 510(k) regulatory clearance for its MONARCH...

Company Drug

Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer

Fineline Cube Mar 14, 2025

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...

Company

Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges

Fineline Cube Mar 14, 2025

China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...

Company Deals

Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology

Fineline Cube Mar 14, 2025

France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...

Company Deals

Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies

Fineline Cube Mar 14, 2025

China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...

Company Deals

Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management

Fineline Cube Mar 14, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...

Policy / Regulatory

China Issues Guidelines for Informatization of Compact County-level Medical Communities

Fineline Cube Mar 14, 2025

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Drug Policy / Regulatory

CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 14, 2025

China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...

Medical Device Policy / Regulatory

China’s NHSA Issues Guidelines for Neurological Medical Services Pricing

Fineline Cube Mar 14, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...

Company

Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth

Fineline Cube Mar 14, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...

Company Digital

Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services

Fineline Cube Mar 14, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company Drug

Jiuzhitang’s Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval

Fineline Cube Mar 13, 2025

China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical...

Posts pagination

1 … 204 205 206 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.